Initial results from CheckMate 032, a Phase 1/2 clinical trial, showed durable responses and encouraging survival with nivolumab-based regimens in SCLC patients after previous platinum-containing regimens. Response-based modeling has been proposed to capture extended OS associated with I-O treatment. We examine the relationship between patients’ response status at a landmark and OS by treatment arm.
Authors: Irene Santi, Caitlin Smare, Ariadna Juarez-Garcia, D. Ross Camidge, Nancy Schoenherr, John R. Penrod, Pranav Abraham, Beata Korytowsky, Yong Yuan
To find out more about this poster you can register to download it here after the ISPOR event.